<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2010-09-14" updated="2019-12-02">
  <drugbank-id primary="true">DB06752</drugbank-id>
  <name>Chymopapain</name>
  <description>Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. It is currently discontinued.[L2487]</description>
  <cas-number>9001-09-6</cas-number>
  <unii>1UK146T40N</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32687</ref-id>
        <pubmed-id>20424870</pubmed-id>
        <citation>Henschke N, Kuijpers T, Rubinstein SM, van Middelkoop M, Ostelo R, Verhagen A, Koes BW, van Tulder MW: Injection therapy and denervation procedures for chronic low-back pain: a systematic review. Eur Spine J. 2010 Sep;19(9):1425-49. doi: 10.1007/s00586-010-1411-0. Epub 2010 Apr 29.</citation>
      </article>
      <article>
        <ref-id>A32688</ref-id>
        <pubmed-id>13888995</pubmed-id>
        <citation>EBATA M, YASUNOBU KT: Chymopapain. I. Isolation, crystallization, and preliminary characterization. J Biol Chem. 1962 Apr;237:1086-94.</citation>
      </article>
      <article>
        <ref-id>A32701</ref-id>
        <pubmed-id>3729572</pubmed-id>
        <citation>Jenner JR, Buttle DJ, Dixon AK: Mechanism of action of intradiscal chymopapain in the treatment of sciatica: a clinical, biochemical, and radiological study. Ann Rheum Dis. 1986 Jun;45(6):441-9.</citation>
      </article>
      <article>
        <ref-id>A32704</ref-id>
        <pubmed-id>15815870</pubmed-id>
        <citation>Kawano K, Tajima N, Hashida S, Ishikawa E: Study of blood metabolism and urinary excretion of chymopapain following intradiscal injection using a high-sensitivity enzyme immunoassay. J Orthop Sci. 2005;10(2):206-13. doi: 10.1007/s00776-004-0872-6.</citation>
      </article>
      <article>
        <ref-id>A32706</ref-id>
        <pubmed-id>6376060</pubmed-id>
        <citation>Simmons JW, Upman PJ, Stavinoha WB: Pharmacologic and toxicologic profile of chymopapain B (Chemolase). Drug Chem Toxicol. 1984;7(3):299-314. doi: 10.3109/01480548409035110.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L2482</ref-id>
        <title>The rise and fall of chemonucleolysis</title>
        <url>http://eknygos.lsmuni.lt/springer/525/351-358.pdf</url>
      </link>
      <link>
        <ref-id>L2486</ref-id>
        <title>Worthington</title>
        <url>http://www.worthington-biochem.com/pcyp/default.html</url>
      </link>
      <link>
        <ref-id>L2487</ref-id>
        <title>FDA approval</title>
        <url>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=018663</url>
      </link>
      <link>
        <ref-id>L2496</ref-id>
        <title>Spine Health</title>
        <url>https://www.spine-health.com/conditions/herniated-disc/whats-a-herniated-disc-pinched-nerve-bulging-disc</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Chymopapain is indicated for the development of chemonucleolysis which is used for the digestion of the nucleus pulposus in patients with disc herniation confirmed by myelography.[A32687] A disc herniation occurs when the outer portion of the spinal disc breaks down and the inner portion (nucleus pulposus) leaks out pressing surrounding nerves and leading to irradiating pain.[L2496] The chemonucleolysis is a non-surgical treatment that involves the injection of an enzyme to dissolve the nucleus pulposus.[L2482]</indication>
  <pharmacodynamics>The first studies showed that after intradiscal injection of chymopapain the effect involved the removal of the nucleus pulposus leaving the annulus intact.[L2482] The clinical reports indicated a spontaneous remission of symptoms after the administration of chymopapain. It is also highly documented an increased urinary excretion of glycosaminoglycans.[A32701]</pharmacodynamics>
  <mechanism-of-action>Chymopapain is thought to degrade proteoglycan content of the intervertebral disc causing loss of glycosaminoglycan and water. This effect will cause the shrinkage of the disc and a reduction of the pressure on the nerve root.[A32701]</mechanism-of-action>
  <toxicity>The median lethal dose of chymopapain in mice is registered to be 82 mg/kg and the toxicity mechanism was caused by hemorrhage due to the destruction of the cement substance in the blood vessels. When administered in an overdosage, chymopapain was able to nearly completely dissolve the nucleus pulposus and cause the disruption of the annulus fibrosus.[A32706]</toxicity>
  <metabolism/>
  <absorption/>
  <half-life>Following intra-discal injection, the level of chymopapain decreases gradually and presents a half-life of 2-3 days. The half-life for urinary excretion is reported to be of about 3 days.[A32704]</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Chymodiactin Injection - 4 Nkat Units/2ml</name>
      <labeller>Knoll Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02170302</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>1999-12-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intradiscal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Chymodiactin Injection - 4 Nkat Units/2ml</name>
      <ingredients>Chymopapain</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Cysteine Endopeptidases</category>
      <mesh-id>D003546</mesh-id>
    </category>
    <category>
      <category>Cysteine Proteases</category>
      <mesh-id>D057056</mesh-id>
    </category>
    <category>
      <category>Endopeptidases</category>
      <mesh-id>D010450</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Musculo-Skeletal System</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intradiscal</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="M09AB01">
      <level code="M09AB">Enzymes</level>
      <level code="M09A">OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM</level>
      <level code="M09">OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM</level>
      <level code="M">MUSCULO-SKELETAL SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB06752.pdf?1524610260</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;sp|P14080|PAPA2_CARPA Chymopapain OS=Carica papaya OX=3649 PE=1 SV=2
MATMSSISKIIFLATCLIIHMGLSSADFYTVGYSQDDLTSIERLIQLFDSWMLKHNKIYE
SIDEKIYRFEIFRDNLMYIDETNKKNNSYWLGLNGFADLSNDEFKKKYVGFVAEDFTGLE
HFDNEDFTYKHVTNYPQSIDWRAKGAVTPVKNQGACGSCWAFSTIATVEGINKIVTGNLL
ELSEQELVDCDKHSYGCKGGYQTTSLQYVANNGVHTSKVYPYQAKQYKCRATDKPGPKVK
ITGYKRVPSNCETSFLGALANQPLSVLVEAGGKPFQLYKSGVFDGPCGTKLDHAVTAVGY
GTSDGKNYIIIKNSWGPNWGEKGYMRLKRQSGNSQGTCGVYKSSYYPFKGFA</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble</value>
      <source>Ebata and Yasunobu. 1961.</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>137-182 ÂºC</value>
      <source>Ebata and Yasunobu. 1961.</source>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>10.2-10.6</value>
      <source>Baines and Brocklehurst, 1982.</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>27000.0</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>2557</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910365</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Chymopapain</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201626</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cons/chymopapain-injection.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0002114</id>
      <name>Bone marrow proteoglycan</name>
      <organism>Humans</organism>
      <actions>
        <action>degradation</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A32701</ref-id>
            <pubmed-id>3729572</pubmed-id>
            <citation>Jenner JR, Buttle DJ, Dixon AK: Mechanism of action of intradiscal chymopapain in the treatment of sciatica: a clinical, biochemical, and radiological study. Ann Rheum Dis. 1986 Jun;45(6):441-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P13727" source="Swiss-Prot">
        <name>Bone marrow proteoglycan</name>
        <general-function>Heparin binding</general-function>
        <specific-function>Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA.</specific-function>
        <gene-name>PRG2</gene-name>
        <locus>11q12</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-16</signal-regions>
        <theoretical-pi>6.64</theoretical-pi>
        <molecular-weight>25205.345</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9362</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PRG2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Y00809</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>34476</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P13727</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PRG2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>BMPG</synonym>
          <synonym>MBP</synonym>
          <synonym>Proteoglycan 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037161|Bone marrow proteoglycan
MKLPLLLALLFGAVSALHLRSETSTFETPLGAKTLPEDEETPEQEMEETPCRELEEEEEW
GSGSEDASKKDGAVESISVPDMVDKNLTCPEEEDTVKVVGIPGCQTCRYLLVRSLQTFSQ
AWFTCRRCYRGNLVSIHNFNINYRIQCSVSALNQGQVWIGGRITGSGRCRRFQWVDGSRW
NFAYWAAHQPWSRGGHCVALCTRGGHWRRAHCLRRLPFICSY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019238|Bone marrow proteoglycan (PRG2)
ATGAAACTCCCCTTACTTCTGGCTCTTCTATTTGGGGCAGTTTCTGCTCTTCATCTAAGG
TCTGAGACTTCCACCTTTGAGACCCCTTTGGGTGCTAAGACGCTGCCTGAGGATGAGGAG
ACACCAGAGCAGGAGATGGAGGAGACCCCTTGCAGGGAGCTGGAGGAAGAGGAGGAGTGG
GGCTCTGGAAGTGAAGATGCCTCCAAGAAAGATGGGGCTGTTGAGTCTATCTCAGTGCCA
GATATGGTGGACAAAAACCTTACGTGTCCTGAGGAAGAGGACACAGTAAAAGTGGTGGGC
ATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGTTTACTTGCCGGAGGTGCTACAGGGGC
AACCTGGTTTCCATCCACAACTTCAATATTAATTATCGAATCCAGTGTTCTGTCAGCGCG
CTCAACCAGGGTCAAGTCTGGATTGGAGGCAGGATCACAGGCTCGGGTCGCTGCAGACGC
TTTCAGTGGGTTGACGGCAGCCGCTGGAACTTTGCGTACTGGGCTGCTCACCAGCCCTGG
TCCCGCGGTGGTCACTGCGTGGCCCTGTGTACCCGAGGAGGCCACTGGCGTCGAGCCCAC
TGCCTCAGAAGACTTCCTTTCATCTGTTCCTACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00059</identifier>
            <name>Lectin_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transport vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carbohydrate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heparin binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to nematode</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-10 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-4 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cytokine biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>